A synthetic lipopeptide agonist of TLR2/TLR6; increases NF-κB activity by 4- and 8-fold in HEK293 cells transfected with TLR2 and TLR6 but not TLR6 alone at 0.1 and 1 nM, respectively; induces the expression of the CCL20, IL-8, IL-1β, and TNF-α in THP-1 cells and, to a lesser extent, in TLR10 knockdown cells at 100 ng/ml; dose-dependently increases the percentage of DM13 and VMM1 melanoma cells expressing CXCL10 when administered in combination with IFN-γ with a maximal increase of 50% at 0.5-50 μg/ml; induces fever and increases plasma levels of IL-6 and TNF-α by greater than 90-fold in rats at 100 μg/kg, i.p.; dose-dependently reduces locomotor activity and both food and water consumption with a maximal reduction of ten grams per 12 hours at 10-1,000 μg/kg, i.p.